Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in High Risk Cutaneous Squamous Cell Carcinoma
NCT04428671Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- May 2020
- Primary completion
- Oct 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Emory University. Primary endpoint: Pathologic response rate up to 10 years. Started May 2020; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04428671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428671.